Physician profile
Jeffrey Factor
NPI 1457332298
$7,391.11
in general payments reported to CMS, 2019-2025
16 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $180 · 2021: $3,682 · 2022: $706 · 2023: $1,145 · 2024: $473 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $3,490.79 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $964.56 | 2019-2024 | Tezspire |
| Glaxosmithkline, LLC. | $904.75 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Genzyme Corporation | $481.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $446.46 | 2019-2023 | Dupixent |
| Leo Pharma INC. | $247.01 | 2023 | Adbry |
| Alk-Abello, INC | $187.79 | 2019-2022 | |
| Adma Biomanufacturing LLC | $151.30 | 2024 | |
| Genentech USA, INC. | $101.64 | 2024 | |
| Csl Behring | $100.67 | 2021-2025 | Haegarda, Andembry |
| Optinose US, INC. | $98.37 | 2019 | |
| Biocryst US Sales Co., LLC | $71.80 | 2025 | Orladeyo |
| Abbvie INC. | $51.66 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $43.01 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $32.38 | 2024 | Hyqvia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Factor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.